Wednesday, July 24, 2024 12:00:47 PM
kabunushi,
CDF is one source but they are likely only to “make room” for a limited number of GBM and rGBM patients as they are obviously already at max spend rate for other cancer types with new drugs. They will certainly fund some GBM and rGBM patients and “might” be able to fund 10-15 patients per month if they prioritize GBM treatment once made available.
Braintrust is a type of hybrid charity and crowdfunding source that works to create awareness of need and support for patients. They are a growing organization that will likely gain more traction as DCVax-L becomes a big new item in the UK.
Cancer Research UK is focused more on research than actual direct care of patients so they would likely provide mostly indirect support. There is another fund that I believe flipper44, myself and others read up on that represented about $600,000,000 of funding source but I am having trouble finding it in my notes right now. That source seemed to be one of the best sources for actual direct patient benefit though. Will let you know when I find it or maybe others will find it first. Best wishes.
CDF is one source but they are likely only to “make room” for a limited number of GBM and rGBM patients as they are obviously already at max spend rate for other cancer types with new drugs. They will certainly fund some GBM and rGBM patients and “might” be able to fund 10-15 patients per month if they prioritize GBM treatment once made available.
Braintrust is a type of hybrid charity and crowdfunding source that works to create awareness of need and support for patients. They are a growing organization that will likely gain more traction as DCVax-L becomes a big new item in the UK.
Cancer Research UK is focused more on research than actual direct care of patients so they would likely provide mostly indirect support. There is another fund that I believe flipper44, myself and others read up on that represented about $600,000,000 of funding source but I am having trouble finding it in my notes right now. That source seemed to be one of the best sources for actual direct patient benefit though. Will let you know when I find it or maybe others will find it first. Best wishes.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
